49results about How to "Reduce reperfusion injury" patented technology

The present invention relates to the therapeutic and prophylactic use of C1 inhibitor for preventing, reducing and treating ischemia and reperfusion injury. The C1 inhibitor of the present invention is still therapeutically effective when administered after an ischemic period and reperfusion and therefore particularly useful for unforeseen occurrences of ischemic reperfusion such as e.g. a stroke.

The present invention relates to methods and compositions related to the use of enzymes of the allene oxide synthase family for reducing myocardial ischemia reperfusion injury associated with myocardial infarction, thrombolysis, angioplasty and coronary bypass surgery. The methods of the invention comprise administration of allene oxide synthases, which are capable of eliminating lipid hydroperoxides, as a potent cardioprotective agent. The invention is based on the discovery that administration of allene oxide synthase following severe global ischemia stimulates cardiac recovery.

This invention proposes an agent to block the “fuel supply” that energizes cancer cell growth by protecting surrounding cells to the cancer, particularly stromal fibroblast cells. The invention disables the products of surrounding cells useable for energy conversion by the cancer cell thereby crippling the cell and disabling its growth process. This application describes the use of a formulation of liposomally encapsulated glutathione that is preferably used orally to increase the level of glutathione in tissues in order to prevent and reverse the metabolic changes in cells that results in the formation of the metabolic fuel that supports cancer cells and to prevent the oxidative stress that damages normal support cells such as fibroblasts and can prevent and reverse these cells from the steps of autophagy and mitophagy that results in the cells decreasing the normal mitochondrial production of ATP for energy and resorting to the use of aerobic glycolysis for energy production. The use of oral liposomally encapsulated glutathione will maintain the presence and normal function of caveolin in fibroblast and other cells, thus preventing their conversion to autophagic tumor stromal cells. By stopping the formation of autophagic cells, the production of the metabolic fuel needed by cancer cells is stopped, which results in the death of the cancer cells. Compositions using liposomally encapsulated glutathione and other compounds that enhance the favorable effects of liposomal glutathione on cancer disease are referenced.

The invention discloses a medical component with taurine and medicine to treat blood vessel of brain and heart disease, preparing method and usage in medical technical domain, which is characterized by the following: choosing the blood vessel of brain and heart disease medicine from one or several tanshinone IIA, medical salt, Notoginsen triterpenes, carthamus tinctorius yellow colour, haw leaf total flavone, puerarin and lamp-dish flower element; choosing tanshinone IIA or medical salt as tanshinone IIA mahogany. This invention can used to treat coronary disease, angina pectoris and so on.

The invention discloses a drug delivery system for percutaneous coronary intervention, which comprises: adenosine; infusion consumables for adenosine infusion; used for catalyzing excessive adenosine metabolism in the body, and Adenosine kinase that activates the downstream AMPK pathway; infusion consumable for infusion of adenosine kinase. The drug delivery system can reduce the retention of adenosine after percutaneous coronary intervention in patients with adenosine kinase mutation or insufficient activity, increase the activity of adenosine kinase, thereby reducing myocardial reperfusion injury and improving the myocardial reperfusion protective effect of adenosine.

The present invention relates to methods and pharmaceutical compositions for cardioprotection of subjects who experienced a myocardial infarction. In particular, the present invention relates to a ligand of the sonic hedgehog signaling pathway for use in the cardioprotection of a subject who experienced a myocardial infarction.